[Skip to Content]
[Skip to Content Landing]
November 2016

Successful Treatment of Refractory Pityriasis Rubra Pilaris With Secukinumab

Author Affiliations
  • 1Department of Dermatology, Medical Center–University of Freiburg, Freiburg, Germany
JAMA Dermatol. 2016;152(11):1278-1279. doi:10.1001/jamadermatol.2016.3885

Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disorder of unknown cause. It is characterized by follicular hyperkeratosis, scaly erythematous plaques, palmoplantar keratoderma, and frequent progression to generalized erythroderma.1 Six types of PRP are distinguished, with type 1 being the most common form in adults. Disease management of PRP is challenging for lack of specific guidelines. Topical emollients, corticosteroids, and salicylic acid alone or combined with systemic retinoids, methotrexate, and tumor necrosis factor (TNF) inhibitors are considered to be most helpful.2,3 Unfortunately, PRP often resists conventional treatment. We report the case of a 67-year-old man with refractory PRP who was successfully treated with secukinumab.

First Page Preview View Large
First page PDF preview
First page PDF preview